257 related articles for article (PubMed ID: 16651439)
1. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
2. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
Porosnicu M; Mian A; Barber GN
Cancer Res; 2003 Dec; 63(23):8366-76. PubMed ID: 14678998
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.
Simpson GR; Coffin RS
Methods Mol Biol; 2009; 542():551-64. PubMed ID: 19565922
[TBL] [Abstract][Full Text] [Related]
4. Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma.
Lu YC; Chen YJ; Yu YR; Lai YH; Cheng JC; Li YF; Shen CH; Tai CK
Oncol Rep; 2012 Jul; 28(1):21-6. PubMed ID: 22552490
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
7. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Dias JD; Liikanen I; Guse K; Foloppe J; Sloniecka M; Diaconu I; Rantanen V; Eriksson M; Hakkarainen T; Lusky M; Erbs P; Escutenaire S; Kanerva A; Pesonen S; Cerullo V; Hemminki A
Clin Cancer Res; 2010 May; 16(9):2540-9. PubMed ID: 20388844
[TBL] [Abstract][Full Text] [Related]
8. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
9. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Ramnaraine M; Pan W; Goblirsch M; Lynch C; Lewis V; Orchard P; Mantyh P; Clohisy DR
Cancer Res; 2003 Oct; 63(20):6847-54. PubMed ID: 14583482
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors.
Bernt KM; Steinwaerder DS; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2002 Nov; 62(21):6089-98. PubMed ID: 12414633
[TBL] [Abstract][Full Text] [Related]
11. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
12. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
14. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
15. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
16. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
Erbs P; Regulier E; Kintz J; Leroy P; Poitevin Y; Exinger F; Jund R; Mehtali M
Cancer Res; 2000 Jul; 60(14):3813-22. PubMed ID: 10919655
[TBL] [Abstract][Full Text] [Related]
17. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
18. Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
Fogar P; Navaglia F; Basso D; Greco E; Zambon CF; Fadi E; Falda A; Stranges A; Vannozzi F; Danesi R; Pedrazzoli S; Plebani M
Pancreas; 2007 Oct; 35(3):224-31. PubMed ID: 17895842
[TBL] [Abstract][Full Text] [Related]
19. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
20. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.
Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R
Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
